China Times (www.chinatimes. Net.. CN.) Reporter Wang Yu and Yu Na report from Beijing
The pharmaceutical index fell 6.01% this week (January 17-21) and fell 2.79% on Friday. It once hit a recent low and then rebounded slightly to close at 13061.49.
Among the top 10 companies in the pharmaceutical sector by market value, 8 stocks fell this week and only 2 rose. The biggest decline was Pharmaron Beijing Co.Ltd(300759) , down 6.63% in the week, closing at 124.28 yuan / share on Friday, and the total market value fell below the 100 billion mark; Its cro sector fell 9.55% this week, and Wuxi Apptec Co.Ltd(603259) , Hangzhou Tigermed Consulting Co.Ltd(300347) also fell more than 5% this week.
In the list, the second largest decline this week was Yunnan Baiyao Group Co.Ltd(000538) , down 6.55% to close at 97.51 yuan / share, with a total market value of 125.069 billion yuan. The Chinese medicine index of Yunnan Baiyao Group Co.Ltd(000538) fell 7.64% this week, of which Beijing Tongrentang Co.Ltd(600085) fell 5% and Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) fell 1.78%.
Only Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) and Zhejiang Nhu Company Ltd(002001) rose in the list this week. Among them, Zhejiang Nhu Company Ltd(002001) increased the most, with a weekly increase of 7.40%. It closed at 31.62 yuan / share on Friday, with a total market value of 81.529 billion yuan; Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) rose 2.49% this week and 5.98% on Friday to close at 51.42 yuan / share, with a total market value of 131.784 billion yuan.
On January 20, the Geneva pharmaceutical patent pool (MPP) announced that it had signed agreements with 27 generic pharmaceutical enterprises to produce and supply high-quality and affordable oral anti-covid-19 generic drugs for 105 low-income countries or regions around the world, so as to promote the affordability and accessibility of oral anti-covid-19 drugs in low-income countries and help local epidemic prevention and control. It is worth noting that the above regions do not include the Chinese market.
Among the 27 enterprises, including 5 Chinese pharmaceutical enterprises, respectively Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Shijiazhuang Longze pharmaceutical and Shanghai deseno are licensed to produce API and finished drug at the same time, and Langhua pharmaceutical under viabio is licensed to produce API.
Affected by this, on Friday, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) rose sharply and Brightgene Bio-Medical Technology Co.Ltd(688166) rose by the limit. In addition, Weiya biology and Jiangsu Aidea Pharmaceutical Co.Ltd(688488) participating in Longze pharmaceutical rose sharply.
On Wednesday, the Guangdong Provincial Drug Trading Center issued the notice on the centralized procurement document of diclofenac and other drugs of Guangdong Alliance (hereinafter referred to as the document). This centralized purchase includes 20 kinds of growth hormone products, involving Changchun High And New Technology Industries (Group) Inc(000661) subsidiaries Kinsey pharmaceutical, Anhui Anke Biotechnology (Group)Co.Ltd(300009) , Novo Nordisk, Haiji biology, unisel, South Korea LG life and other enterprises.
This time, the price of growth hormone water injection fell by 70%, far exceeding the 10% decline of powder injection, which exceeded the market expectation. Changchun High And New Technology Industries (Group) Inc(000661) fell sharply. The share price fell by the limit for three consecutive days and closed at 184.36 yuan / share on Friday. The share price was 522.17 yuan / share from last year’s high, down more than 60%.
On Friday, Changchun High And New Technology Industries (Group) Inc(000661) announced that out of recognition of the company’s long-term value and confidence in the company’s future development, some executives increased their holdings of the company’s shares through the secondary market with self raised funds. The average price of this increase was 184.36 yuan / share, with a total of 84700 shares. In addition, the company completed the repurchase plan issued on November 23 last year on Friday. The actual share repurchase time range is from December 3, 2021 to January 21, 2022. 2473201 shares of the company have been repurchased, accounting for 0.61% of the total share capital of the company, of which the highest transaction price is 308.35 yuan / share and the lowest transaction price is 184.36 yuan / share, with a total transaction amount of about 600 million yuan (including transaction costs).
